Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2020-12-07 Declaration of Voting R…
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 3, 2020, reporting the submission of matters to a vote of security holders at the 2020 Annual Meeting of Stockholders. It details the election results of directors and the ratification of the independent registered public accounting firm. The content focuses on the official results of shareholder votes at the annual meeting, which aligns with the category for Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4073 characters, which is relatively short but contains detailed voting results, not just an announcement of a report. Therefore, it is not a Report Publication Announcement (RPA). It is not a management or financial report, nor a proxy solicitation or presentation. Hence, the best fit is DVA.
2020-12-07 English
8-K
Call Transcript Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 3, 2020, by Galectin Therapeutics Inc. It states that the company made a presentation after its Annual Meeting of Stockholders and that a transcript of this presentation is attached as Exhibit 99.1. The document itself is a current report disclosing Regulation FD information and includes a transcript of a presentation. The key phrase is 'transcript of presentation' attached, indicating this is a transcript of a conference call or presentation. The document length is 3482 characters, which is relatively short and consistent with a Form 8-K filing that includes a transcript. The transcript is of a presentation after the Annual Meeting, which aligns with a conference call or investor presentation transcript. Therefore, the document is best classified as a Call Transcript (CT).
2020-12-03 English
FORM 4 SUBMISSION
Director's Dealing
2020-12-01 English
FORM 4 SUBMISSION
Director's Dealing
2020-11-17 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2020, by Galectin Therapeutics Inc. It announces the results of operations and financial condition for the three and nine months ended September 30, 2020, and includes a press release as an exhibit. The document states that the information is being furnished, not filed, and incorporates a press release announcing financial results. The content corresponds to an initial announcement of quarterly financial results, which aligns with the definition of an Earnings Release (ER). The document is about 4603 characters, which is consistent with a typical earnings release filing rather than a full interim report. Therefore, the appropriate classification is Earnings Release (ER).
2020-11-09 English
FORM S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by Galectin Therapeutics Inc. It registers shares to be issued under an equity incentive plan. The document includes legal and regulatory disclosures typical of a securities registration statement under the Securities Act of 1933. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to securities registration and issuance. Form S-8 filings are not explicitly listed in the provided categories, but the closest relevant category is 'Regulatory Filings (RNS)' which covers general regulatory announcements and filings that do not fit other categories. The document is not an announcement of a report but the actual registration statement itself, which is a regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-11-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.